Ieq Capital LLC Acquires Shares of 194,189 Ventyx Biosciences, Inc. $VTYX

Key Points

• Ieq Capital LLC acquired 194,189 shares of Ventyx Biosciences, valued at approximately $223,000, representing about 0.27% of the company's stock.
• Ventyx Biosciences' stock is currently trading at $2.52, with a 52-week range between $0.78 and $3.39.
• Analysts have upgraded Ventyx Biosciences from a "sell" to a "hold" rating, with a consensus target price of $7.50.

Ieq Capital LLC bought a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 194,189 shares of the company's stock, valued at approximately $223,000. Ieq Capital LLC owned approximately 0.27% of Ventyx Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Bank of America Corp DE boosted its position in Ventyx Biosciences by 376.4% during the 4th quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock valued at $9,359,000 after acquiring an additional 3,376,446 shares in the last quarter. Vestal Point Capital LP boosted its position in Ventyx Biosciences by 15.9% during the 4th quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company's stock valued at $4,380,000 after acquiring an additional 275,000 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Ventyx Biosciences in the 4th quarter worth $3,903,000. Millennium Management LLC boosted its position in shares of Ventyx Biosciences by 369.7% in the 4th quarter. Millennium Management LLC now owns 1,281,629 shares of the company's stock worth $2,807,000 after purchasing an additional 1,008,760 shares in the last quarter. Finally, Monaco Asset Management SAM boosted its position in shares of Ventyx Biosciences by 372.7% in the 1st quarter. Monaco Asset Management SAM now owns 1,134,444 shares of the company's stock worth $1,305,000 after purchasing an additional 894,444 shares in the last quarter. Institutional investors own 97.88% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Ventyx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Ventyx Biosciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Ventyx Biosciences Price Performance

VTYX traded down $0.08 on Friday, reaching $2.30. 462,313 shares of the stock were exchanged, compared to its average volume of 418,492. The company's 50-day moving average price is $2.68 and its 200 day moving average price is $1.95. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $3.39. The firm has a market capitalization of $164.01 million, a PE ratio of -1.37 and a beta of 0.95.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.07. As a group, equities analysts forecast that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.